giovedì 8 gennaio 2015

Should Amgen Break Itself Up?

In the wake of yesterday’s pharma-deal madness (Novartis swapping assets with GlaxoSmithKline and selling its animal health division to Eli Lilly; Valeant and Bill Ackman making a hostile bid for Botox-maker Allergan), Bernstein analyst Geoffrey Porges sent a note out to investors asking what it might all mean for biotech […]



Should Amgen Break Itself Up?

Nessun commento:

Posta un commento